Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 10/20 | 0.48 |
| ▸ | MAPT | P10636 | 3/20 | 0.48 |
| ▸ | NPC1 | O15118 | 2/20 | 0.48 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | AHR | P35869 | 1/20 | 0.48 |
| ▸ | PLK1 | P53350 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 6/20 | 0.45 |
| ▸ | HPGD | P15428 | 5/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 4/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4498608 | 0.84 | NPC1 (0.53) | KDM4EMAPTNPC1RAB9AAHR | |
| SCHEMBL4849720 | 0.82 | EDNRA (0.46) | KDM4ENPC1RAB9AHSD17B10HPGD | |
| SCHEMBL13925859 | 0.81 | KDM4E (0.40) | KDM4ERAB9AHSD17B10HPGDTSHR | |
| SCHEMBL13255440 | 0.80 | P2RX7 (0.42) | KDM4EMAPTNPC1RAB9AHSD17B10 | |
| SCHEMBL4859908 | 0.79 | KDM4E (0.46) | KDM4EMAPTNPC1RAB9AAHR | |
| SCHEMBL8482263 | 0.78 | KDM4E (0.68) | KDM4EMAPTNPC1RAB9AAHR | |
| SCHEMBL31475455 | 0.78 | KDM4E (0.68) | KDM4EMAPTNPC1RAB9AAHR | |
| SCHEMBL13255592 | 0.76 | L3MBTL1 (0.37) | KDM4ENPC1RAB9AHSD17B10HPGD | |
| SCHEMBL16505027 | 0.75 | KDM4E (0.46) | KDM4EMAPTNPC1RAB9AAHR | |
| SCHEMBL754304 | 0.75 | KDM4E (0.63) | KDM4EMAPTRAB9AAHRPLK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7759372-B2 | Nitrogen-containing heteroaryl compounds having inhibitory activity against HIV integrase | SHIONOGI & CO., LTD. (JP) | 2010-07-20 | — | — | US | disclosed |
| US-7759372-B2 | Nitrogen-containing heteroaryl compounds having inhibitory activity against HIV integrase | SHIONOGI & CO., LTD. (JP) | 2010-07-20 | — | — | US | disclosed |
| EP-2033952-A1 | Nitrogen-containing Heteroaryl compounds having HIV Integrase Inhibitory Activity | Shionogi&Co., Ltd. (JP) | 2009-03-11 | — | — | EP | disclosed |
| US-7456192-B2 | 3β-amino azabicyclooctane heteroaromatic amid derivatives preparation method and therapeutic uses thereof | PIERRE FABRE MEDICAMENT (FR) | 2008-11-25 | — | — | US | disclosed |
| EP-1375486-B1 | NITROGEN-CONTAINING HETEROARYL COMPOUNDS HAVING HIV INTEGRASE INHIBITORY ACTIVITY | SHIONOGI & CO (JP) | 2008-10-15 | — | — | EP | disclosed |
| EP-1440075-B1 | NOVEL 3BETA-AMINO AZABICYCLOOCTANE HETEROAROMATIC AMIDE DERIVATIVES, PREPARATION METHOD AND THERAPEUTIC USES THEREOF | PF MEDICAMENT (FR) | 2005-06-08 | — | — | EP | disclosed |
| US-20050080085-A1 | Novel 3beta-amino azabicyclooctane heteroaromatic amid derivatives preparation method and therapeutic uses thereof | PIERRE FABRE MEDICAMENT (FR) | 2005-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050080085-A1 | Novel 3beta-amino azabicyclooctane heteroaromatic amid derivatives preparation method and therapeutic uses thereof | AOC3, MAOB, AOC1 | KDM4E 2970/4885MAPT 4210/4885NPC1 2179/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.